Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) EBIAT (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed EBIAT for 16 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 15916.67% to -$2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$56.7 million through Dec 2025, down 357.07% year-over-year, with the annual reading at -$56.7 million for FY2025, 357.07% down from the prior year.
  • EBIAT for Q4 2025 was -$2.8 million at Harvard Bioscience, down from -$1.2 million in the prior quarter.
  • The five-year high for EBIAT was $2.4 million in Q2 2022, with the low at -$50.3 million in Q1 2025.
  • Average EBIAT over 5 years is -$4.1 million, with a median of -$1.5 million recorded in 2022.
  • The sharpest move saw EBIAT soared 693.9% in 2022, then crashed 15916.67% in 2025.
  • Over 5 years, EBIAT stood at $961000.0 in 2021, then crashed by 273.36% to -$1.7 million in 2022, then dropped by 9.12% to -$1.8 million in 2023, then surged by 100.99% to $18000.0 in 2024, then plummeted by 15916.67% to -$2.8 million in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$2.8 million, -$1.2 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.